John Muir was one of the first climbers to explore and climb many of the peaks in Yosemite Valley in California’s High Sierra. During his first ascent of Mount Ritter in 1872, he became gripped with fear.
Kerfuffle! (pt 1)
A kerfuffle is the polite term for a cascading series of errors that can be initiated by a seemingly innocuous event that then leads to other errors that seem to gain in severity and impact. Kerfuffles can appear in any line of work or play that involves a linked series of tasks with downstream implications. In fact, the modeling and simulation activities performed to support model-based drug development have the potential to produce a catalogue of kerfuffles that can culminate in the failure to deliver modeling and simulation results when they are needed for decision-making. Kerfuffles often have their origins in inadvertent oversights committed early in the study design and data collection process or in the commonplace shortcuts taken to deliver preliminary (“quick-and-dirty”) results for internal use.
Simulations Plus Announces Share Repurchase Program
Up to $2.5 million over 12 months authorized by board of directors
Modeling Effects of Exenatide on the Pharmacokinetics of Acetaminophen, Digoxin, and Warfarin
Exenatide, a 39-amino acid peptide used for treatment of type 2 diabetes, is known to inhibit gastric emptying and as a result to alter the absorption of orally administered concomitant medications.
Simulations Plus Signs Another Collaboration Agreement
Companies to Cooperate on Development of Advanced Ocular Delivery Simulation
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of liposome-entrapped paclitaxel...
Structural Requirements for Drug Inhibition of the Liver Specific Human Organic Cation Transport Protein 1
The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib.
U.S. FDA Licenses ADMET Predictor™ from Simulations Plus
Adds Property Prediction Software to Earlier GastroPlus(™) Licenses
U.S. National Institutes of Health Renews ClassPharmer Software Licenses
Chemical Genomics Center Renews Five Licenses
Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption.
The purpose of this study was to investigate the suitability of physicochemical parameters of Active Pharmaceutical Ingredients (APIs) as input functions for the Advanced Compartmental Absorption and Transit Model...
Simulations Plus and Roche Sign Multi-year Collaboration
Collaboration to Develop Drug-Drug Interaction Capability in GastroPlus™
Simulations Plus Subsidiary, Words+, Inc., Releases Major New Product
"Conversa(™)" System Offers 12-inch Touch Tablet With Superior Voice Quality And Volume
A cellular conformation-based screen for androgen receptor inhibitors
The androgen receptor (AR), a member of the steroid nuclear receptor family of transcription factors, regulates a wide range of physiological...
Simulations Plus Reports Third Quarter and Nine Months FY2008 Financial Results
Record revenues achieved in both business units
Mechanistic Modeling of Metoprolol Absorption and Pharmacokinetics from Immediate and Modified Release Formulations
As one of the most widely used b-blocking agents, metoprolol is also a popular drug in research studies. A number of published studies describe the pharmacokinetics as well as the pharmacodynamics of…
Simulations Plus Sets Date for Third Quarter Earnings Release and Conference Call
Conference Call to be on Tuesday, July 15, at 4:15 PM EDT
Simulations Plus Releases Major Software Update for its Top Rated Predictive Software
ADMET Predictor™ 3.0 Employs New Technology for Molecular Descriptors, All New Predictive Models
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability
The nucleoside analog R1479 is a potent and highly selective inhibitor of NS5b-directed hepatitis C virus (HCV) RNA polymerase in vitro.
Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data
Analogous to the fraction unbound in microsomes (fumic), fraction unbound in hepatocyte incubations (fuhep) is an important parameter in the prediction of intrinsic clearance and potential drug-drug interactions.